Hoffman K, Leichtling G, Shin S, Seaman A, Gailey T, Spencer H
Addict Sci Clin Pract. 2025; 20(1):10.
PMID: 39923115
PMC: 11806898.
DOI: 10.1186/s13722-025-00541-6.
Ghosh A, Sharma B, Sood A, Sharma K
Indian J Psychiatry. 2025; 66(12):1101-1123.
PMID: 39867231
PMC: 11758978.
DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_770_24.
Strong-Jones S, Brant K, Kreager D, Harrison E, Jones A
BMC Glob Public Health. 2024; 2(1):26.
PMID: 39681943
PMC: 11622996.
DOI: 10.1186/s44263-024-00058-1.
Moore K, Phillips S, Kromash R, Siebert S, Roberts W, Peltier M
Stigma Health. 2024; 9(2):224-235.
PMID: 39381322
PMC: 11456775.
DOI: 10.1037/sah0000483.
Figgatt M, Jaiswal J, Bassler J, Gagnon K, Mulrain M, Reed-Pickens H
J Assoc Nurses AIDS Care. 2024; 35(6):556-562.
PMID: 39259518
PMC: 11561755.
DOI: 10.1097/JNC.0000000000000502.
Exploring the Lived Experiences of Medication for Opioid use Disorder Treatment: A Qualitative Study among a Crowdsourced Convenience Sample.
Victor G, Kheibari A, Strickland J
Community Ment Health J. 2024; 61(3):411-419.
PMID: 39235576
PMC: 11868299.
DOI: 10.1007/s10597-024-01345-9.
Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder.
Freet C, Evans B, Brick T, Deneke E, Wasserman E, Ballard S
Addict Sci Clin Pract. 2024; 19(1):56.
PMID: 39061093
PMC: 11282646.
DOI: 10.1186/s13722-024-00481-7.
Evaluating generative AI responses to real-world drug-related questions.
Giorgi S, Isman K, Liu T, Fried Z, Sedoc J, Curtis B
Psychiatry Res. 2024; 339:116058.
PMID: 39059040
PMC: 11705880.
DOI: 10.1016/j.psychres.2024.116058.
Variability in Practice of Buprenorphine Treatment by Emergency Department Operational Characteristics.
Comstock G, Truszczynski N, Michael S, Hoppe J
West J Emerg Med. 2024; 25(4):483-489.
PMID: 39028234
PMC: 11254146.
DOI: 10.5811/westjem.18019.
Web-Based Forums for People Experiencing Substance Use or Gambling Disorders: Scoping Review.
Peart A, Horn F, Petukhova R, Barnett A, Lubman D
JMIR Ment Health. 2024; 11:e49010.
PMID: 38885012
PMC: 11217707.
DOI: 10.2196/49010.
"They Ask Questions, But They Don't Want the Answers"-Perceptions of Clinical Communication Among Veterans Discontinuing Buprenorphine for the Treatment of Opioid Use Disorder.
Eckhardt A, Waller D, Shull S, Lovejoy T, Morasco B, Gordon A
Subst Use Addctn J. 2024; 45(4):674-681.
PMID: 38767274
PMC: 11458360.
DOI: 10.1177/29767342241251761.
The Elephant in the Room: A Systematic Review of the Application and Effects of Psychological Treatments for Pregnant Women with Dual Pathology (Mental Health and Substance-Related Disorders).
Caro-Canizares I, Lopez Carpintero N, Carmona-Camacho R
Int J Environ Res Public Health. 2024; 21(4).
PMID: 38673305
PMC: 11050033.
DOI: 10.3390/ijerph21040392.
First-hand accounts of structural stigma toward people who use opioids on Reddit.
Eschliman E, Choe K, DeLucia A, Addison E, Jackson V, Murray S
Soc Sci Med. 2024; 347:116772.
PMID: 38502980
PMC: 11031276.
DOI: 10.1016/j.socscimed.2024.116772.
Identifying structural risk factors for overdose following incarceration: a concept mapping study.
Nall S, Jurecka C, Ammons Jr A, Rodriguez A, Craft B, Waleed C
Health Justice. 2024; 12(1):11.
PMID: 38472497
PMC: 10936003.
DOI: 10.1186/s40352-024-00265-w.
Evaluation of Two Videos that Apply Evidence-Based Strategies to Increase Self-Efficacy and Reduce Opioid-Related Stigma Among Medical Students.
Eschliman E, Choe K, Fei Y, Kang C, Koetje J, Harocopos A
Acad Psychiatry. 2024; 48(2):123-134.
PMID: 38388788
PMC: 10954387.
DOI: 10.1007/s40596-024-01945-3.
Expanding access to medication treatment for opioid use disorders: Findings from the Washington State hub and spoke effort.
Stewart M, Daily S, Thomas C, Panas L, Ritter G, Reif S
Drug Alcohol Depend. 2024; 256:111125.
PMID: 38368666
PMC: 10922849.
DOI: 10.1016/j.drugalcdep.2024.111125.
Mobile treatment for opioid use disorder: Implementation of community-based, same-day medication access interventions.
Chatterjee A, Baker T, Rudorf M, Walt G, Stotz C, Martin A
J Subst Use Addict Treat. 2023; 159:209272.
PMID: 38128649
PMC: 10947870.
DOI: 10.1016/j.josat.2023.209272.
Frame Shift: Focusing on Harm Reduction and Shared Decision Making for People Who Use Drugs Hospitalized With Infections.
Thakarar K, Appa A, Abdul Mutakabbir J, Goff A, Brown 3rd J, Tuell C
Clin Infect Dis. 2023; 78(2):e12-e26.
PMID: 38018174
PMC: 11487100.
DOI: 10.1093/cid/ciad664.
Latent class analysis of perceived stigma among older adults receiving medications for opioid use disorder.
Mitchell M, Angelo S, Akinwolere O, Perkins M, Bender A
J Subst Use Addict Treat. 2023; 156:209187.
PMID: 37858796
PMC: 10843650.
DOI: 10.1016/j.josat.2023.209187.
A conceptual framework for how structural changes in emerging acute substance use service models can reduce stigma of medications for opioid use disorder.
Becker T, Eschliman E, Thakrar A, Yang L
Front Psychiatry. 2023; 14:1184951.
PMID: 37829763
PMC: 10565357.
DOI: 10.3389/fpsyt.2023.1184951.
